Biomira retains Financial Dynamics as communications advisor

EDMONTON, July 26 /CNW/ - Biomira Inc. (Nasdaq:BIOM) (TSX:BRA) today
announced that Financial Dynamics has been hired by the Company to provide
proactive, strategic communications counsel specifically as it relates to
media and investor relations.
Alex McPherson, M.D., Ph.D., President and CEO of Biomira, stated, "As
our Company continues to grow and reach important clinical milestones, we need
to articulate Biomira's story to a wider and more diverse audience. This is
especially important as we move toward commencing the BLP25 Liposome Vaccine
phase 3 study, currently planned to start by the end of 2005 and prepare for
next steps with our third generation product candidate, BGLP40 Liposome
Vaccine. We have appointed Financial Dynamics to assist us with our
communications due to their sector knowledge, international reach and proven
track record in advising companies in our industry."
Declan Kelly, Chief Executive Officer of Financial Dynamics, commented,
"We are pleased to have been appointed by Biomira, and look forward to working
with management as the Company moves into the next stage of its development."

Biomira Inc.
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy. We are The Cancer
Vaccine People(TM).

Financial Dynamics
Financial Dynamics is a leading global communications agency serving
hundreds of corporations - large and small, public and private - with
strategic communications programs and high-impact media relations. Financial
Dynamics uses its international network, with headquarters in New York and
London, to coordinate cross-border communications programs for some of the
world's most reputable corporate brands.
Further information about Financial Dynamics can be obtained on the
company's web site at www.fd-us.com or by calling 212-850-5600.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing and results
of clinical trials and the potential impact of our communications initiatives.
Although the Company believes that the forward-looking statements contained
herein are reasonable, it can give no assurance that the Company's
expectations are correct. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.